217 related articles for article (PubMed ID: 17270033)
1. Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma cells.
Kanamori T; Shimizu M; Okuno M; Matsushima-Nishiwaki R; Tsurumi H; Kojima S; Moriwaki H
Cancer Sci; 2007 Mar; 98(3):431-7. PubMed ID: 17270033
[TBL] [Abstract][Full Text] [Related]
2. Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells.
Tatebe H; Shimizu M; Shirakami Y; Sakai H; Yasuda Y; Tsurumi H; Moriwaki H
Cancer Lett; 2009 Nov; 285(2):210-7. PubMed ID: 19520494
[TBL] [Abstract][Full Text] [Related]
3. Synergistic growth inhibition by 9-cis-retinoic acid plus trastuzumab in human hepatocellular carcinoma cells.
Tatebe H; Shimizu M; Shirakami Y; Tsurumi H; Moriwaki H
Clin Cancer Res; 2008 May; 14(9):2806-12. PubMed ID: 18451248
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid.
Matsushima-Nishiwaki R; Okuno M; Takano Y; Kojima S; Friedman SL; Moriwaki H
Carcinogenesis; 2003 Aug; 24(8):1353-9. PubMed ID: 12807734
[TBL] [Abstract][Full Text] [Related]
5. Synergistic growth inhibition of human hepatocellular carcinoma cells by acyclic retinoid and GW4064, a farnesoid X receptor ligand.
Ohno T; Shirakami Y; Shimizu M; Kubota M; Sakai H; Yasuda Y; Kochi T; Tsurumi H; Moriwaki H
Cancer Lett; 2012 Oct; 323(2):215-22. PubMed ID: 22579649
[TBL] [Abstract][Full Text] [Related]
6. Strategy and mechanism for the prevention of hepatocellular carcinoma: phosphorylated retinoid X receptor alpha is a critical target for hepatocellular carcinoma chemoprevention.
Shimizu M; Takai K; Moriwaki H
Cancer Sci; 2009 Mar; 100(3):369-74. PubMed ID: 19068086
[TBL] [Abstract][Full Text] [Related]
7. Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIP1) and inhibition of expression of cyclin D1.
Suzui M; Masuda M; Lim JT; Albanese C; Pestell RG; Weinstein IB
Cancer Res; 2002 Jul; 62(14):3997-4006. PubMed ID: 12124333
[TBL] [Abstract][Full Text] [Related]
8. Role of acyclic retinoid in the chemoprevention of hepatocellular carcinoma: basic aspects, clinical applications, and future prospects.
Shimizu M; Imai K; Takai K; Moriwaki H
Curr Cancer Drug Targets; 2012 Nov; 12(9):1119-28. PubMed ID: 22873214
[TBL] [Abstract][Full Text] [Related]
9. Synergistic induction of apoptosis by acyclic retinoid and interferon-beta in human hepatocellular carcinoma cells.
Obora A; Shiratori Y; Okuno M; Adachi S; Takano Y; Matsushima-Nishiwaki R; Yasuda I; Yamada Y; Akita K; Sano T; Shimada J; Kojima S; Okano Y; Friedman SL; Moriwaki H
Hepatology; 2002 Nov; 36(5):1115-24. PubMed ID: 12395321
[TBL] [Abstract][Full Text] [Related]
10. [Clinical application of vitamin K for hepatocellular carcinoma].
Mizuta T; Ozaki I
Clin Calcium; 2007 Nov; 17(11):1693-9. PubMed ID: 17982189
[TBL] [Abstract][Full Text] [Related]
11. Synergistic growth inhibition by acyclic retinoid and phosphatidylinositol 3-kinase inhibitor in human hepatoma cells.
Baba A; Shimizu M; Ohno T; Shirakami Y; Kubota M; Kochi T; Terakura D; Tsurumi H; Moriwaki H
BMC Cancer; 2013 Oct; 13():465. PubMed ID: 24103747
[TBL] [Abstract][Full Text] [Related]
12. Acyclic retinoid in the chemoprevention of hepatocellular carcinoma (review).
Kojima S; Okuno M; Matsushima-Nishiwaki R; Friedman SL; Moriwaki H
Int J Oncol; 2004 Apr; 24(4):797-805. PubMed ID: 15010815
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effects of acyclic retinoid and OSI-461 on growth inhibition and gene expression in human hepatoma cells.
Shimizu M; Suzui M; Deguchi A; Lim JT; Xiao D; Hayes JH; Papadopoulos KP; Weinstein IB
Clin Cancer Res; 2004 Oct; 10(19):6710-21. PubMed ID: 15475462
[TBL] [Abstract][Full Text] [Related]
14. Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D1 expression through inhibition of nuclear factor kappaB activation.
Ozaki I; Zhang H; Mizuta T; Ide Y; Eguchi Y; Yasutake T; Sakamaki T; Pestell RG; Yamamoto K
Clin Cancer Res; 2007 Apr; 13(7):2236-45. PubMed ID: 17404108
[TBL] [Abstract][Full Text] [Related]
15. Pharmaceutical and nutraceutical approaches for preventing liver carcinogenesis: chemoprevention of hepatocellular carcinoma using acyclic retinoid and branched-chain amino acids.
Shimizu M; Shirakami Y; Hanai T; Imai K; Suetsugu A; Takai K; Shiraki M; Moriwaki H
Mol Nutr Food Res; 2014 Jan; 58(1):124-35. PubMed ID: 24273224
[TBL] [Abstract][Full Text] [Related]
16. Cyclooxygenase-2 inhibitor and interferon-beta synergistically induce apoptosis in human hepatoma cells in vitro and in vivo.
Nakamoto N; Higuchi H; Kanamori H; Kurita S; Tada S; Takaishi H; Toda K; Yamada T; Kumagai N; Saito H; Hibi T
Int J Oncol; 2006 Sep; 29(3):625-35. PubMed ID: 16865278
[TBL] [Abstract][Full Text] [Related]
17. Acyclic retinoid inhibits diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BLKS/J- +(db)/+Lepr(db) mice.
Shimizu M; Sakai H; Shirakami Y; Iwasa J; Yasuda Y; Kubota M; Takai K; Tsurumi H; Tanaka T; Moriwaki H
Cancer Prev Res (Phila); 2011 Jan; 4(1):128-36. PubMed ID: 21071580
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of retinoid X receptor alpha at serine 260 impairs its metabolism and function in human hepatocellular carcinoma.
Matsushima-Nishiwaki R; Okuno M; Adachi S; Sano T; Akita K; Moriwaki H; Friedman SL; Kojima S
Cancer Res; 2001 Oct; 61(20):7675-82. PubMed ID: 11606411
[TBL] [Abstract][Full Text] [Related]
19. Acyclic retinoid, a novel synthetic retinoid, induces growth inhibition, apoptosis, and changes in mRNA expression of cell cycle- and differentiation-related molecules in human colon carcinoma cells.
Suzui M; Sunagawa N; Chiba I; Moriwaki H; Yoshimi N
Int J Oncol; 2006 May; 28(5):1193-9. PubMed ID: 16596235
[TBL] [Abstract][Full Text] [Related]
20. (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis.
Shirakami Y; Shimizu M; Adachi S; Sakai H; Nakagawa T; Yasuda Y; Tsurumi H; Hara Y; Moriwaki H
Cancer Sci; 2009 Oct; 100(10):1957-62. PubMed ID: 19558547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
